ImmunityBio’s (IBRX) Buy Rating Reiterated at HC Wainwright

ImmunityBio (NASDAQ:IBRX)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They presently have a $15.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 93.30% from the company’s current price.

A number of other analysts also recently weighed in on IBRX. The Goldman Sachs Group restated a “buy” rating on shares of ImmunityBio in a research report on Monday, February 23rd. BTIG Research set a $12.00 target price on ImmunityBio in a research report on Friday, May 8th. Weiss Ratings restated a “sell (d-)” rating on shares of ImmunityBio in a research report on Tuesday, April 14th. D. Boral Capital restated a “buy” rating and issued a $23.00 target price on shares of ImmunityBio in a research report on Tuesday, May 5th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $12.00 target price (up from $7.00) on shares of ImmunityBio in a report on Wednesday, March 4th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $14.20.

ImmunityBio Price Performance

Shares of ImmunityBio stock opened at $7.76 on Wednesday. The firm has a market cap of $8.13 billion, a PE ratio of -9.13 and a beta of 0.02. ImmunityBio has a 1 year low of $1.95 and a 1 year high of $12.43. The company has a 50 day simple moving average of $7.78 and a two-hundred day simple moving average of $5.49.

ImmunityBio (NASDAQ:IBRX) last released its earnings results on Thursday, May 7th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.54). The company had revenue of $44.21 million during the quarter, compared to analyst estimates of $43.07 million. As a group, research analysts anticipate that ImmunityBio will post -0.31 earnings per share for the current year.

Insider Buying and Selling at ImmunityBio

In other news, Director Barry J. Simon sold 165,000 shares of the firm’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $10.25, for a total transaction of $1,691,250.00. Following the completion of the transaction, the director directly owned 2,925,821 shares in the company, valued at $29,989,665.25. This trade represents a 5.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christobel Selecky sold 25,000 shares of the firm’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $10.00, for a total value of $250,000.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 275,000 shares of company stock valued at $2,934,500 over the last 90 days. Corporate insiders own 69.48% of the company’s stock.

Institutional Investors Weigh In On ImmunityBio

Large investors have recently added to or reduced their stakes in the stock. Western Wealth Management LLC bought a new stake in ImmunityBio in the 1st quarter worth approximately $44,000. Geneos Wealth Management Inc. lifted its holdings in ImmunityBio by 579.3% in the first quarter. Geneos Wealth Management Inc. now owns 5,754 shares of the company’s stock valued at $44,000 after acquiring an additional 4,907 shares during the period. Archer Investment Corp lifted its holdings in ImmunityBio by 67.1% in the first quarter. Archer Investment Corp now owns 5,872 shares of the company’s stock valued at $45,000 after acquiring an additional 2,358 shares during the period. Hodges Capital Management Inc. bought a new stake in ImmunityBio during the first quarter valued at approximately $77,000. Finally, Aaron Wealth Advisors LLC bought a new position in ImmunityBio in the 1st quarter worth $78,000. Institutional investors own 8.58% of the company’s stock.

Key Stories Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: The FDA accepted ImmunityBio’s supplemental BLA for ANKTIVA plus BCG in BCG-unresponsive non-muscle invasive bladder cancer with papillary disease and set a PDUFA date of January 6, 2027, keeping a key regulatory path alive for a potential label expansion. Article Title
• Positive Sentiment: ImmunityBio also announced five new U.S. patents for ANKTIVA in combination with BCG, extending intellectual-property protection through 2035 and improving the long-term commercial outlook for the franchise. Article Title
• Neutral Sentiment: Analyst commentary highlighted the company’s bladder-cancer opportunity and broader solid-tumor potential, reinforcing the growth narrative around ANKTIVA. Article Title
• Negative Sentiment: Multiple law firms issued class-action reminders and deadline alerts related to alleged misleading cancer-treatment claims and prior FDA warning-letter concerns, adding legal risk and potential distraction for investors. Article Title

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.